Physician profile
Peter N Schochet
NPI 1578593190
$6,037.26
in general payments reported to CMS, 2019-2025
24 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 88% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $832 · 2021: $840 · 2022: $663 · 2023: $608 · 2024: $932 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.11 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,554.47 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $723.62 | 2019-2025 | Dupixent |
| Genzyme Corporation | $605.49 | 2019-2025 | |
| Sobi, INC | $487.48 | 2019-2023 | |
| Covis Pharma Gmbh | $450.38 | 2019-2021 | |
| Baxter Healthcare | $376.79 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $290.54 | 2019-2025 | Vest Therapy Und |
| Biogen, INC. | $275.24 | 2023-2025 | Spinraza, Skyclarys, Qalsody |
| Glaxosmithkline, LLC. | $257.50 | 2019-2021 | |
| Advanced Respiratory, INC | $218.44 | 2019-2021 | |
| Amgen INC. | $206.26 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $201.09 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $72.27 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $43.16 | 2021-2022 | |
| Electromed, INC. | $41.16 | 2024-2025 | Smartvest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $38.55 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2020-2023 | Ofev |
| Azurity Pharmaceuticals, INC. | $35.53 | 2025 | Alvesco |
| Acadia Pharmaceuticals INC | $27.29 | 2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $25.33 | 2024 | Elaprase |
| Alcresta Therapeutics, INC. | $22.94 | 2024 | Relizorb |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Aytu Biopharma, INC. | $15.77 | 2020 | |
| Circassia INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schochet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.